Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Karl Douglas Lewis

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone720/848-0584

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res. 2017 Jun; 27(3):189-199. PMID: 28296713.
      View in: PubMed
    2. Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients aged =65 years with advanced basal cell carcinoma. Oncotarget. 2016 11 15; 7(46):76118-76124. PMID: 27764798.
      View in: PubMed
    3. Medina TM, Lewis KD. The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib. Onco Targets Ther. 2016; 9:3739-52. PMID: 27382311; PMCID: PMC4922803.
    4. Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Higgins SA, Ho AL, Lewis KD, Lydiatt DD, Nehal KS, Nghiem P, Olsen EA, Schmults CD, Sekulic A, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Wong SL, Zic JA, Hoffmann KG, Engh A. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 May; 14(5):574-97. PMID: 27160235.
      View in: PubMed
    5. Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Cornélis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul; 75(1):113-125.e5. PMID: 27067394.
      View in: PubMed
    6. Schmitt RJ, Kreidler SM, Glueck DH, Amaria RN, Gonzalez R, Lewis K, Bagrosky BM, Kwak JJ, Koo PJ. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nucl Med Commun. 2016 Feb; 37(2):122-8. PMID: 26440571; PMCID: PMC4689629 [Available on 02/01/17].
    7. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8. PMID: 26811525.
      View in: PubMed
    8. Merkow J, Paniccia A, Jones E, Jones T, Hodges M, Stovall R, Kounalakis N, Gajdos C, Lewis K, Robinson W, Gonzalez R, Pearlman N, McCarter M. Association of sentinel lymph node diameter with melanoma metastasis. Am J Surg. 2016 Aug; 212(2):315-20. PMID: 26827186.
      View in: PubMed
    9. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18. PMID: 26115796.
      View in: PubMed
    10. Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72(6):1021-6.e8. PMID: 25981002.
      View in: PubMed
    11. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 01; 33(25):2780-8. PMID: 26014293.
      View in: PubMed
    12. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun; 16(6):716-28. PMID: 25981810.
      View in: PubMed
    13. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704. PMID: 25287827; PMCID: PMC4226803.
    14. Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother. 2014 Sep; 37(7):360-5. PMID: 25075565; PMCID: PMC4127096.
    15. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65. PMID: 25037139.
      View in: PubMed
    16. Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014 Jun 18; 311(23):2397-405. PMID: 24938562; PMCID: PMC4249701.
    17. Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Rojas PB, Schwartz JD, Bedikian AY. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer. 2014 Aug; 50(12):2099-107. PMID: 24930625.
      View in: PubMed
    18. Bichakjian CK, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Ho AL, Lewis KD, Lydiatt DD, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Perlis CS, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Werchniak AE, Wong SL, Zic JA, McMillian N, Hoffman K, Ho M. Dermatofibrosarcoma protuberans, version 1.2014. J Natl Compr Canc Netw. 2014 Jun; 12(6):863-8. PMID: 24925197.
      View in: PubMed
    19. Bichakjian CK, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Ho AL, Lewis KD, Lydiatt DD, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Perlis CS, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Werchniak AE, Wong SL, Zic JA, Hoffmann KG, McMillian NR, Ho M. Merkel cell carcinoma, version 1.2014. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):410-24. PMID: 24616545.
      View in: PubMed
    20. McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, Hou J, Wang L, Yue H, Hauschild A. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014 Mar; 50(4):774-83. PMID: 24412051.
      View in: PubMed
    21. Koo PJ, Klingensmith WC, Lewis KD, Bagrosky BM, Gonzalez R. Anti-CTLA4 antibody therapy related complications on FDG PET/CT. Clin Nucl Med. 2014 Jan; 39(1):e93-6. PMID: 23657138.
      View in: PubMed
    22. Kudchadkar RR, Gonzalez R, Lewis K. New targeted therapies in melanoma. Cancer Control. 2013 Oct; 20(4):282-8. PMID: 24077404.
      View in: PubMed
    23. Garrett K, Okuyama S, Jones W, Barnes D, Tran Z, Spencer L, Lewis K, Maroni P, Chesney M, Marcus A. Bridging the transition from cancer patient to survivor: pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) program. Patient Educ Couns. 2013 Aug; 92(2):266-72. PMID: 23647980; PMCID: PMC4687454.
    24. Jones EL, Jones TS, Pearlman NW, Gao D, Stovall R, Gajdos C, Kounalakis N, Gonzalez R, Lewis KD, Robinson WA, McCarter MD. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013 May; 148(5):456-61. PMID: 23325294; PMCID: PMC3856253.
    25. Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013 May 15; 19(10):2766-74. PMID: 23575478; PMCID: PMC3694426.
    26. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74. PMID: 23569304.
      View in: PubMed
    27. Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 01; 19(5):1232-43. PMID: 23434733.
      View in: PubMed
    28. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9. PMID: 23248257; PMCID: PMC4878037.
    29. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236. PMID: 23171508; PMCID: PMC3543342.
    30. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 11 01; 367(18):1694-703. PMID: 23020132; PMCID: PMC3549295.
    31. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9. PMID: 22805292; PMCID: PMC4109286.
    32. Amaria RN, Bowles DW, Lewis KD, Jimeno A. Vismodegib in basal cell carcinoma. Drugs Today (Barc). 2012 Jul; 48(7):459-67. PMID: 22844657.
      View in: PubMed
    33. Kounalakis N, Gao D, Gonzalez R, Becker M, Lewis K, Poust J, Pearlman N, Robinson W, McCarter M. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy. 2012 Jul; 4(7):679-86. PMID: 22853754; PMCID: PMC3883760.
    34. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 07; 366(23):2171-9. PMID: 22670903.
      View in: PubMed
    35. Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, Norris DA, Roop DR, Spritz RA, Ahn NG, Fujita M. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-50. PMID: 22622430; PMCID: PMC3434242.
    36. Kudchadkar R, Lewis K, Gonzalez R. Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors. Semin Oncol. 2012 Apr; 39(2):139-44. PMID: 22484185.
      View in: PubMed
    37. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb; 31(1):115-25. PMID: 22415798.
      View in: PubMed
    38. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23; 366(8):707-14. PMID: 22356324; PMCID: PMC3724515.
    39. Amaria RN, Lewis KD, Jimeno A. Vemurafenib: the road to personalized medicine in melanoma. Drugs Today (Barc). 2012 Feb; 48(2):109-18. PMID: 22384451.
      View in: PubMed
    40. Scheier B, Amaria R, Lewis K, Gonzalez R. Novel therapies in melanoma. Immunotherapy. 2011 Dec; 3(12):1461-9. PMID: 22091682.
      View in: PubMed
    41. Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, Gonzalez R, Lewis K, Norris DA, Shellman YG. ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open. 2012 Feb 15; 1(2):92-100. PMID: 23213401; PMCID: PMC3507205.
    42. Amaria RN, Lewis KD, Gonzalez R. Therapeutic options in cutaneous melanoma: latest developments. Ther Adv Med Oncol. 2011 Sep; 3(5):245-51. PMID: 21957431; PMCID: PMC3169931.
    43. Prado R, Jensen JD, Okamoto M, Luo Y, Lewis KD, Fujita M. Metastatic melanoma manifesting with purulent nodules composed of neutrophils and melanoma cells. Eur J Dermatol. 2011 Jul-Aug; 21(4):642-3. PMID: 21840791.
      View in: PubMed
    44. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 Apr 08; 6:34. PMID: 21477295; PMCID: PMC3094365.
    45. Okuyama S, Gonzalez R, Lewis KD. Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review. Core Evid. 2010 Oct 21; 5:39-48. PMID: 21042541; PMCID: PMC2963921.
    46. Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J, Amatruda TT, Hersh E, Richards J, Weber JS, Hoon DS. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010 Apr 15; 16(8):2402-8. PMID: 20371696; PMCID: PMC2855775.
    47. Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 2010 Mar 01; 16(5):1613-23. PMID: 20179232.
      View in: PubMed
    48. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs. 2011 Apr; 29(2):340-6. PMID: 20084425; PMCID: PMC4331064.
    49. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E, Gonzalez R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011 Feb; 29(1):161-6. PMID: 19830389.
      View in: PubMed
    50. Fujita M, High WA, Asgari S, Lewis KD, Gonzalez R. Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature. Int J Dermatol. 2009 Apr; 48(4):426-30. PMID: 19335434.
      View in: PubMed
    51. Kudchadkar R, Gonzalez R, Robinson W, Becker M, Treichel K, Kimura A, Lewis K. The absent-minded professor: an unusual complication of melanoma. Oncology (Williston Park). 2008 Dec; 22(14):1609-14. PMID: 19198219.
      View in: PubMed
    52. Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs. 2008 Nov; 17(11):1769-76. PMID: 18922112.
      View in: PubMed
    53. Baumgartner JM, Gonzalez R, Lewis KD, Robinson WA, Richter DA, Palmer BE, Wilson CC, McCarter MD. Increased survival from stage IV melanoma associated with fewer regulatory T Cells. J Surg Res. 2009 Jun 01; 154(1):13-20. PMID: 19062042.
      View in: PubMed
    54. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85. PMID: 18445842.
      View in: PubMed
    55. Kudchadkar R, Gonzalez R, Lewis K, Treichel K, Hammerman S, Robinson W, Fitzpatrick J, Gonzalez R, Kavanagh B, Rusthoven K. A case of Merkel cell carcinoma. Oncology (Williston Park). 2008 Mar; 22(3):322-8. PMID: 18494357.
      View in: PubMed
    56. Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs. 2008 Feb; 26(1):89-94. PMID: 17891338.
      View in: PubMed
    57. McCarter MD, Baumgartner J, Escobar GA, Richter D, Lewis K, Robinson W, Wilson C, Palmer BE, Gonzalez R. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007 Oct; 14(10):2854-60. PMID: 17593331.
      View in: PubMed
    58. Pearlman NW, McCarter MD, Frank M, Hurtubis C, Merkow RP, Franklin WA, Gonzalez R, Lewis K, Roaten JB, Robinson WA. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg. 2006 Dec; 192(6):878-81. PMID: 17161112.
      View in: PubMed
    59. Ravdel L, Robinson WA, Lewis K, Gonzalez R. Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol. 2006 Aug 01; 94(2):101-4. PMID: 16847918.
      View in: PubMed
    60. Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63. PMID: 16809738.
      View in: PubMed
    61. Lewis KD, Dollarhide S, Fitzpatrick JE, Gonzalez R, High WA, McCarter MD, Olsen C, Raben D. Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass. Oncology (Williston Park). 2006 Jun; 20(7):763-70. PMID: 16841798.
      View in: PubMed
    62. Qutub W, Lewis K, Gonzalez R, Quaife R, Russ P, McCarter M. Lymphangiomatosis masquerading as metastatic melanoma. Am Surg. 2006 Apr; 72(4):367-70. PMID: 16676867.
      View in: PubMed
    63. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Kuo C, Wang HJ, Milford R, Morton DL, Hoon DS. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res. 2006 Feb 15; 12(4):1137-43. PMID: 16489066; PMCID: PMC2856464.
    64. Lewis KD, Thompson JA, Weber JS, Robinson WA, O'Day S, Lutzky J, Legha SS, Floret S, Ruvuna F, Gonzalez R. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs. 2006 Jan; 24(1):89-94. PMID: 16379038.
      View in: PubMed
    65. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang HJ, Elashoff RM, Takeuchi H, Umetani N, Hoon DS. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005 Nov 01; 23(31):8057-64. PMID: 16258104; PMCID: PMC2856446.
    66. Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest. 2005; 23(4):303-8. PMID: 16100942.
      View in: PubMed
    67. Lewis KD, Gonzalez R, Robinson WA, Fitzpatrick JE, McCarter MD, Braden C. A young woman with melanoma diagnosed during pregnancy. Oncology (Williston Park). 2004 Jun; 18(7):794-9. PMID: 15255167.
      View in: PubMed
    68. Bergen M, Lewis K, Chen R, Kenney T, Glode LM. Prostate cancer on the internet: impact on patients and how technology helps physicians and researchers. Clin Prostate Cancer. 2003 Mar; 1(4):227-34. PMID: 15040881.
      View in: PubMed
    Lewis's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)